| Literature DB >> 34083235 |
Alexander M Menzies1,2,3, Richard A Scolyer1,2,4, Georgina V Long5,2,3.
Abstract
Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti-PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future.See related article by Najjar et al., p. 4195. ©2021 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34083235 DOI： 10.1158/1078-0432.CCR-21-1236
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531